Malaria's Key to the Liver is Uncovered

Article

Scientists uncover a port of liver entry for malaria parasites in a report published in the Journal of Experimental Medicine. If these results hold up in humans, drugs that target this entry protein might help prevent the spread of disease.

This illustration shows how the protein receptor CD68 acts as a gateway for a malaria parasite (sporozoite) to enter the liver through a Kupffer cell, as revealed by Cha et al. Illustration courtesy of Cha et al.

Scientists uncover a port of liver entry for malaria parasites in a report published in the Journal of Experimental Medicine. If these results hold up in humans, drugs that target this entry protein might help prevent the spread of disease.

Malaria is caused by a parasite called Plasmodium falciparum, which is transmitted to humans via mosquito bite. Recent efforts to limit parasite transmission and increase treatment coverage has reduced the number of malaria-related deaths, but the parasite still causes roughly 200 million new infections and half a million deaths worldwide each year.

The first stop for malaria parasites in humans is the liver, where a few organisms multiply into tens of thousands, which are then released into the bloodstream. Passage through the liver is essential for the parasite to establish a productive infection and cause disease, and the bug's entry route has been traced to specialized liver cells called Kupffer cells. But exactly how the parasite traverses these cells is not clear.

A team of scientists at Johns Hopkins Bloomberg School of Public Health now find that a Kupffer cell protein called CD68 is needed for parasite passage and efficient liver infection, as mice lacking CD68 had 70 percent fewer parasites in their livers compared to intact animals. If this reduction is sufficient to substantially limit blood infections (and thus disease), CD68 may represent a potential new drug target in the fight against malaria.

Reference: Cha, S.-J., et al. 2015. J. Exp. Med. doi:10.1084/jem.20110575

Source: Journal of Experimental Medicine/Rockefeller University Press

Related Videos
Antimicrobial Resistance (Adobe Stock unknown)
Anne Meneghetti, MD, speaking with Infection Control Today
Patient Safety: Infection Control Today's Trending Topic for March
Infection Control Today® (ICT®) talks with John Kimsey, vice president of processing optimization and customer success for Steris.
Picture at AORN’s International Surgical Conference & Expo 2024
Infection Control Today and Contagion are collaborating for Rare Disease Month.
Rare Disease Month: An Infection Control Today® and Contagion® collaboration.
Vaccine conspiracy theory vector illustration word cloud  (Adobe Stock 460719898 by Colored Lights)
Rare Disease Month: An Infection Control Today® and Contagion® collaboration.
Related Content